SCHEMBL25758613

SCHEMBL25758613

O=S(=O)(NCCCCN1CCN(CCCc2ccccc2)CC1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 7/20 0.64
▸ HTR1A P08908 4/20 0.60
▸ ALDH1A1 P00352 2/20 0.58
▸ TP53 P04637 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ SIGMAR1 Q99720 2/20 0.54
▸ HTR2A P28223 3/20 0.51
▸ DRD2 P14416 2/20 0.51
▸ KCNH2 Q12809 2/20 0.51
▸ DRD4 P21917 1/20 0.51
▸ ADRA1D P25100 1/20 0.51
▸ ADRA1A P35348 1/20 0.51
▸ ADRA1B P35368 1/20 0.51
▸ DRD3 P35462 1/20 0.51
▸ SLC6A4 P31645 1/20 0.51
▸ HTR2B P41595 1/20 0.51
▸ MBTD1 Q05BQ5 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ HTR6 P50406 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29022586 0.96 HTR7 (0.69) HTR7HTR1AALDH1A1TP53GAA
SCHEMBL25758620 0.88 HTR7 (0.53) HTR7HTR1AALDH1A1TP53GAA
SCHEMBL24069058 0.86 HTR7 (0.85) HTR7HTR1AALDH1A1HTR2AMBTD1
SCHEMBL29022575 0.84 HTR7 (0.57) HTR7ALDH1A1TP53GAASIGMAR1
SCHEMBL13889021 0.84 ALDH1A1 (0.81) ALDH1A1TP53GAAMAPT
SCHEMBL25290527 0.84 SLC6A2 (0.59) HTR7HTR1ASIGMAR1KCNH2SLC6A4
SCHEMBL29022599 0.81 HTR1A (0.74) HTR7HTR1AHTR2AHTR6
SCHEMBL25758490 0.81 HTR7 (0.72) HTR7ALDH1A1GAASIGMAR1MAPT
SCHEMBL24069429 0.80 SLC6A2 (0.63) HTR7SIGMAR1KCNH2SLC6A4MAPT
SCHEMBL12672472 0.80 HTR7 (0.83) HTR7HTR1AALDH1A1HTR2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 — — CN claimed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 HTR7 79/4885HTR1A 34/4885ALDH1A1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback